Johnson & Johnson is transforming the trajectory of lung cancer by advancing important innovations and accelerating the development of new applications for this deadly disease. Our strategy is built on recognizing the inherent heterogeneity of lung cancer and developing therapies for novel targets based on the unique biology of disease subgroups. By leveraging our extensive oncology experience, we have capabilities across a wide array of modalities, including small molecules, multi-specifics, antibody drug conjugates and radioligand therapeutics.
Through the development of the first bispecific antibody in lung cancer, we aim to bring renewed hope fin EGFR-mutated non-small cell lung cancer (NSCLC) where less than 20% of patients are alive after five years, and between 25% and 40% never get the chance to receive a subsequent therapy after first-line treatment. Building on the promise of this bispecific antibody, our rapidly expanding development program in lung cancer includes both monotherapy and combination strategies, with the potential to build standard-of-care treatment regimens.
Worldwide, lung cancer is one of the most common cancers. In 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths. Non-small cell lung cancer makes up 80 to 85 percent of all lung cancer cases.
Johnson & Johnson is also focused on building external collaborations to further advance the science of lung cancer. Our focus includes research and development efforts in non-small cell lung cancer (squamous and adenocarcinoma) as well as small cell lung cancer.
Lung cancer by the numbers
- Leading cause of cancer deaths worldwide
- Second most common cancer in both men and women
- Claims more lives than colon, breast, and prostate cancers combined
- Worldwide, lung cancer is one of the most common cancers. In 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths. NSCLC makes up 80 to 85 percent of all lung cancer cases.
- The 5-year survival rate for NSCLC is less than 20%
